Cargando…
The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up
BACKGROUND: Endoscopic Retrograde Cholangiopancreatography (ERCP), used for choledocholithiasis treatment, carries a risk of pyogenic liver abscess (PLA) due to communication between the biliary system and bowel contents. However, limited data exists on this issue. This study aims to identify the ri...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505383/ https://www.ncbi.nlm.nih.gov/pubmed/37724089 http://dx.doi.org/10.2147/IDR.S428125 |
_version_ | 1785106908540043264 |
---|---|
author | Liu, An-Che Tai, Wei-Chen Chiu, Shao-Ming Sou, Fai-Meng Yang, Shih-Cheng Lu, Lung-Sheng Kuo, Chung-Mou Chiu, Yi-Chun Chuah, Seng-Kee Liang, Chih-Ming Wu, Cheng-Kun |
author_facet | Liu, An-Che Tai, Wei-Chen Chiu, Shao-Ming Sou, Fai-Meng Yang, Shih-Cheng Lu, Lung-Sheng Kuo, Chung-Mou Chiu, Yi-Chun Chuah, Seng-Kee Liang, Chih-Ming Wu, Cheng-Kun |
author_sort | Liu, An-Che |
collection | PubMed |
description | BACKGROUND: Endoscopic Retrograde Cholangiopancreatography (ERCP), used for choledocholithiasis treatment, carries a risk of pyogenic liver abscess (PLA) due to communication between the biliary system and bowel contents. However, limited data exists on this issue. This study aims to identify the risk factors pertaining to liver abscesses following ERCP lithotomy. METHODS: We conducted a retrospective case series across multiple centers to evaluate patients who developed PLA after ERCP for choledocholithiasis. Data was obtained from the Chung Gung Research Database (January 2001 to December 2018). Out of 220 enrolled patients, 195 were categorized in the endoscopic sphincterotomy (ES) group, while 25 were in the non-ES group for further analysis. RESULTS: The non-ES group had significantly higher total bilirubin levels compared to the ES group (4.3 ± 5.8 vs 1.9 ± 2.0, p<0.001). Abscess size, location, and distribution (single or multiple) were similar between the two groups. The most common pathogens were Klebsiella pneumoniae and Escherichia coli. Pseudomonas infection was significantly less prevalent in the ES group compared to the non-ES group (3.6% vs 16.7%, p=0.007). Patients with concurrent malignancies (HR: 9.529, 95% CI: 2.667–34.048, p=0.001), elevated total bilirubin levels (HR: 1.246, 95% CI: 1.062–1.461, p=0.007), multiple abscess lesions (HR: 5.146, 95% CI: 1.777–14.903, p=0.003), and growth of enterococcus pathogens (HR: 4.518, 95% CI: 1.290–15.823, p=0.001) faced a significantly higher risk of in-hospital mortality. CONCLUSION: PLA incidence was higher in the ES group compared to the non-ES group following ERCP for choledocholithiasis. Attention should be given to significant risk factors, including concurrent malignancies, elevated total bilirubin levels, multiple abscess lesions, and growth of enterococcus pathogens, to reduce in-hospital mortality. |
format | Online Article Text |
id | pubmed-10505383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105053832023-09-18 The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up Liu, An-Che Tai, Wei-Chen Chiu, Shao-Ming Sou, Fai-Meng Yang, Shih-Cheng Lu, Lung-Sheng Kuo, Chung-Mou Chiu, Yi-Chun Chuah, Seng-Kee Liang, Chih-Ming Wu, Cheng-Kun Infect Drug Resist Original Research BACKGROUND: Endoscopic Retrograde Cholangiopancreatography (ERCP), used for choledocholithiasis treatment, carries a risk of pyogenic liver abscess (PLA) due to communication between the biliary system and bowel contents. However, limited data exists on this issue. This study aims to identify the risk factors pertaining to liver abscesses following ERCP lithotomy. METHODS: We conducted a retrospective case series across multiple centers to evaluate patients who developed PLA after ERCP for choledocholithiasis. Data was obtained from the Chung Gung Research Database (January 2001 to December 2018). Out of 220 enrolled patients, 195 were categorized in the endoscopic sphincterotomy (ES) group, while 25 were in the non-ES group for further analysis. RESULTS: The non-ES group had significantly higher total bilirubin levels compared to the ES group (4.3 ± 5.8 vs 1.9 ± 2.0, p<0.001). Abscess size, location, and distribution (single or multiple) were similar between the two groups. The most common pathogens were Klebsiella pneumoniae and Escherichia coli. Pseudomonas infection was significantly less prevalent in the ES group compared to the non-ES group (3.6% vs 16.7%, p=0.007). Patients with concurrent malignancies (HR: 9.529, 95% CI: 2.667–34.048, p=0.001), elevated total bilirubin levels (HR: 1.246, 95% CI: 1.062–1.461, p=0.007), multiple abscess lesions (HR: 5.146, 95% CI: 1.777–14.903, p=0.003), and growth of enterococcus pathogens (HR: 4.518, 95% CI: 1.290–15.823, p=0.001) faced a significantly higher risk of in-hospital mortality. CONCLUSION: PLA incidence was higher in the ES group compared to the non-ES group following ERCP for choledocholithiasis. Attention should be given to significant risk factors, including concurrent malignancies, elevated total bilirubin levels, multiple abscess lesions, and growth of enterococcus pathogens, to reduce in-hospital mortality. Dove 2023-09-13 /pmc/articles/PMC10505383/ /pubmed/37724089 http://dx.doi.org/10.2147/IDR.S428125 Text en © 2023 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liu, An-Che Tai, Wei-Chen Chiu, Shao-Ming Sou, Fai-Meng Yang, Shih-Cheng Lu, Lung-Sheng Kuo, Chung-Mou Chiu, Yi-Chun Chuah, Seng-Kee Liang, Chih-Ming Wu, Cheng-Kun The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up |
title | The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up |
title_full | The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up |
title_fullStr | The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up |
title_full_unstemmed | The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up |
title_short | The Clinical Presentations of Liver Abscess Development After Endoscopic Retrograde Cholangiopancreatography with Choledocholithiasis: A 17-Year Follow-Up |
title_sort | clinical presentations of liver abscess development after endoscopic retrograde cholangiopancreatography with choledocholithiasis: a 17-year follow-up |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505383/ https://www.ncbi.nlm.nih.gov/pubmed/37724089 http://dx.doi.org/10.2147/IDR.S428125 |
work_keys_str_mv | AT liuanche theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT taiweichen theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT chiushaoming theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT soufaimeng theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT yangshihcheng theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT lulungsheng theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT kuochungmou theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT chiuyichun theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT chuahsengkee theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT liangchihming theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT wuchengkun theclinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT liuanche clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT taiweichen clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT chiushaoming clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT soufaimeng clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT yangshihcheng clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT lulungsheng clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT kuochungmou clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT chiuyichun clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT chuahsengkee clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT liangchihming clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup AT wuchengkun clinicalpresentationsofliverabscessdevelopmentafterendoscopicretrogradecholangiopancreatographywithcholedocholithiasisa17yearfollowup |